➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Moodys
Dow
Medtronic
Express Scripts

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,120,727

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,120,727 protect, and when does it expire?

Patent 9,120,727 protects XENLETA and is included in one NDA.

This patent has thirty-five patent family members in twenty-five countries.

Summary for Patent: 9,120,727
Title:Process for the preparation of pleuromutilins
Abstract: Process for the preparation of a compound of formula I ##STR00001## in the form of a single stereoisomer in crystalline form, comprising deprotecting the amine group in a compound of formula IIa ##STR00002## or in a mixture of a compound of formula IIa with a compound of formula IIb ##STR00003## and isolating a compound of formula I from the reaction mixture; compounds and salts of compounds of formula I in crystalline form; pharmaceutical compositions comprising such salts; processes for the preparation of intermediates and intermediates in a process for the preparation of a compound of formula I.
Inventor(s): Riedl; Rosemarie (Vienna, AT), Heilmayer; Werner (Zillingtal, AT), Spence; Lee (Vienna, AT)
Assignee: NABRIVA THERAPEUTICS AG (Vienna, AT)
Application Number:13/699,589
Patent Claim Types:
see list of patent claims
Composition; Compound; Process;

Drugs Protected by US Patent 9,120,727

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Nabriva XENLETA lefamulin acetate TABLET;ORAL 211672-001 Aug 19, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,120,727

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10450092May 26, 2010
PCT Information
PCT FiledMay 23, 2011PCT Application Number:PCT/AT2011/000237
PCT Publication Date:December 01, 2011PCT Publication Number: WO2011/146954

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Boehringer Ingelheim
Moodys
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.